AU2016369623A1 - Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof - Google Patents

Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof Download PDF

Info

Publication number
AU2016369623A1
AU2016369623A1 AU2016369623A AU2016369623A AU2016369623A1 AU 2016369623 A1 AU2016369623 A1 AU 2016369623A1 AU 2016369623 A AU2016369623 A AU 2016369623A AU 2016369623 A AU2016369623 A AU 2016369623A AU 2016369623 A1 AU2016369623 A1 AU 2016369623A1
Authority
AU
Australia
Prior art keywords
ser
thr
val
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016369623A
Other languages
English (en)
Inventor
Sanela Bilic
John Scott CAMERON
Danny Roland Howard Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2016369623A1 publication Critical patent/AU2016369623A1/en
Priority to AU2020201057A priority Critical patent/AU2020201057A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
AU2016369623A 2015-12-17 2016-12-19 Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof Abandoned AU2016369623A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020201057A AU2020201057A1 (en) 2015-12-17 2020-02-13 Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562269044P 2015-12-17 2015-12-17
US62/269,044 2015-12-17
US201662291651P 2016-02-05 2016-02-05
US62/291,651 2016-02-05
PCT/US2016/067430 WO2017106810A2 (fr) 2015-12-17 2016-12-19 Combinaison d'un inhibiteur de c-met avec une molécule d'anticorps dirigée contre pd-1 et ses utilisations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020201057A Division AU2020201057A1 (en) 2015-12-17 2020-02-13 Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof

Publications (1)

Publication Number Publication Date
AU2016369623A1 true AU2016369623A1 (en) 2018-06-28

Family

ID=57956367

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016369623A Abandoned AU2016369623A1 (en) 2015-12-17 2016-12-19 Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof
AU2020201057A Abandoned AU2020201057A1 (en) 2015-12-17 2020-02-13 Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020201057A Abandoned AU2020201057A1 (en) 2015-12-17 2020-02-13 Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof

Country Status (11)

Country Link
US (2) US20200261573A1 (fr)
EP (1) EP3389713A2 (fr)
JP (1) JP2019502695A (fr)
KR (1) KR20180094977A (fr)
CN (1) CN108697794A (fr)
AU (2) AU2016369623A1 (fr)
CA (1) CA3007421A1 (fr)
HK (1) HK1254635A1 (fr)
IL (1) IL259729A (fr)
RU (1) RU2018125603A (fr)
WO (1) WO2017106810A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868202C (fr) 2012-04-03 2021-08-10 Novartis Ag Produits combines comprenant des inhibiteurs de tyrosine kinase et leur utilisation
WO2019161320A1 (fr) * 2018-02-17 2019-08-22 Apollomics Inc. Traitement du cancer à l'aide d'une combinaison d'un modulateur de neutrophiles avec un modulateur de point de contrôle immunitaire
WO2019180576A1 (fr) * 2018-03-20 2019-09-26 Novartis Ag Combinaisons pharmaceutiques
KR102221755B1 (ko) * 2018-05-02 2021-03-02 (주)에임드바이오 c-Met에 특이적으로 결합하는 항체 및 그의 용도
WO2019212253A1 (fr) * 2018-05-02 2019-11-07 사회복지법인 삼성생명공익재단 Anticorps se liant de manière spécifique à c-met et utilisation associée
WO2022007752A1 (fr) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 Nouvelle forme cristalline d'un composé benzamide et de son dichlorhydrate et procédé de préparation correspondant
WO2023051669A1 (fr) * 2021-09-30 2023-04-06 正大天晴药业集团南京顺欣制药有限公司 Combinaison médicamenteuse de dérivé de quinoléine et d'anticorps anti-cd47

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4433059A (en) 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
JPH021556A (ja) 1988-06-09 1990-01-05 Snow Brand Milk Prod Co Ltd ハイブリッド抗体及びその作製方法
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (fr) 1989-07-12 1991-01-24 Genetics Institute, Inc. Animaux chimeriques et transgeniques pouvant produire des anticorps humains
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1992003917A1 (fr) 1990-08-29 1992-03-19 Genpharm International Recombinaison homologue dans des cellules de mammiferes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh Fusionsproteine von monomeren und dimeren von antikörperfragmenten
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
DE69318016D1 (de) 1992-05-08 1998-05-20 Creative Biomolecules Inc Mehrwertige Chimäre Proteine Anologe und Verfahren zu deren Anwendungen
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2162823T5 (es) 1992-08-21 2010-08-09 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US5844094A (en) 1992-09-25 1998-12-01 Commonwealth Scientific And Industrial Research Organization Target binding polypeptide
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
GB9323648D0 (en) 1992-11-23 1994-01-05 Zeneca Ltd Proteins
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
WO1995009917A1 (fr) 1993-10-07 1995-04-13 The Regents Of The University Of California Anticorps bispecifiques et tetravalents, obtenus par genie genetique
WO1996013583A2 (fr) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Hetero-association ciblee de proteines recombinees et de complexes fonctionnels
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JPH11508126A (ja) 1995-05-23 1999-07-21 モルフォシス ゲゼルシャフト ファー プロテインオプティマイルング エムベーハー 多量体タンパク質
WO1997014719A1 (fr) 1995-10-16 1997-04-24 Unilever N.V. Analogue de fragment d'anticorps bifonctionnel ou bivalent
JP2000508892A (ja) 1996-04-04 2000-07-18 ユニリーバー・ナームローゼ・ベンノートシャープ 多価および多特異的抗原結合タンパク
AU7266898A (en) 1997-04-30 1998-11-24 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
CA2304254C (fr) 1997-06-11 2012-05-22 Hans Christian Thogersen Module formant des trimeres
US6670453B2 (en) 1997-10-27 2003-12-30 Unilever Patent Holdings B.V. Multivalent antigen-binding proteins
EP1049787B1 (fr) 1998-01-23 2004-11-24 Vlaams Interuniversitair Instituut voor Biotechnologie Derives d'anticorps a usages multiples
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
ATE251181T1 (de) 1998-07-28 2003-10-15 Micromet Ag Heterominikörper
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
ES2528794T3 (es) 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
EP1299419A2 (fr) 2000-05-24 2003-04-09 Imclone Systems, Inc. Proteines bispecifiques de liaison a l'antigene du type immunoglobulines, et procede de production correspondant
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
CA2417185A1 (fr) 2000-07-25 2002-01-31 Shui-On Leung Proteine de liaison cible multivalente
US20040242847A1 (en) 2000-10-20 2004-12-02 Naoshi Fukushima Degraded agonist antibody
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2002072635A2 (fr) 2001-03-13 2002-09-19 University College London Elements de liaison specifiques
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
ES2276735T3 (es) 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
WO2003049684A2 (fr) 2001-12-07 2003-06-19 Centocor, Inc. Constructions de pseudo-anticorps
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
ATE512989T1 (de) 2002-04-15 2011-07-15 Chugai Pharmaceutical Co Ltd Verfahren zur herstellung von scdb-bibliotheken
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
GB0305702D0 (en) 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
WO2004094613A2 (fr) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Complexe proteinique polyvalent
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
JP5026072B2 (ja) 2003-07-01 2012-09-12 イミューノメディクス、インコーポレイテッド 二重特異性抗体の多価キャリヤー
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
WO2005062916A2 (fr) 2003-12-22 2005-07-14 Centocor, Inc. Methodes permettant de generer des molecules multimeres
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US8383575B2 (en) 2004-01-30 2013-02-26 Paul Scherrer Institut (DI)barnase-barstar complexes
WO2006107617A2 (fr) 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methodes de generation de complexes lies stablement composes d'homodimeres, d'homotetrameres ou de dimeres de dimeres et utilisations associees
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
CA2577082A1 (fr) 2004-09-02 2006-03-16 Genentech, Inc. Molecules heteromultimeriques
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CA2605024C (fr) 2005-04-15 2018-05-22 Macrogenics, Inc. Di-anticorps covalents et leurs utilisations
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DE602005018477D1 (de) 2005-08-26 2010-02-04 Pls Design Gmbh Bivalente IgY Antikörperkonstrukte für diagnostische und therapeutische Anwendungen
WO2007044887A2 (fr) 2005-10-11 2007-04-19 Transtarget, Inc. Procede de production d'une population homogene d'anticorps bispecifiques tetravalents
US8623356B2 (en) 2005-11-29 2014-01-07 The University Of Sydney Demibodies: dimerization-activated therapeutic agents
MY162590A (en) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
JP2009526857A (ja) 2006-02-15 2009-07-23 イムクローン・リミテッド・ライアビリティ・カンパニー 機能性抗体
CA2646508A1 (fr) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Compositions polypeptidiques stabilisees
US8946391B2 (en) 2006-03-24 2015-02-03 The Regents Of The University Of California Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
ES2469676T3 (es) 2006-05-25 2014-06-18 Bayer Intellectual Property Gmbh Complejos moleculares dim�ricos
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
JP2009539413A (ja) 2006-06-12 2009-11-19 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド エフェクター機能を有する単鎖多価結合タンパク質
EP2040546A4 (fr) * 2006-06-22 2009-12-23 Merck & Co Inc Inhibiteurs de tyrosine kinase
US8497246B2 (en) 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
EP2471816A1 (fr) 2006-08-30 2012-07-04 Genentech, Inc. Anticorps multi-spécifiques
WO2008140477A2 (fr) 2006-11-02 2008-11-20 Capon Daniel J Immunoglobulines hybrides présentant des parties mobiles
JP5572388B2 (ja) 2006-11-22 2014-08-13 インサイト・コーポレイション キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン
EP2626372B1 (fr) 2007-03-29 2018-03-21 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
WO2008131242A1 (fr) 2007-04-18 2008-10-30 Zymogenetics, Inc. Fc à chaîne simple, procédés de fabrication et procédés de traitement
JP2010535032A (ja) 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
WO2009021754A2 (fr) 2007-08-15 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Anticorps monospécifiques et multispécifiques, et procédés d'utilisation
EP2650311A3 (fr) 2007-11-27 2014-06-04 Ablynx N.V. Séquences d'acides aminés dirigées contre des cytokines hétérodimériques et/ou leurs récepteurs et polypeptides les comprenant
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
US7893081B2 (en) * 2007-12-20 2011-02-22 Merck & Co., Inc. Tyrosine kinase inhibitors
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
CN104114579B (zh) 2011-10-27 2020-01-24 健玛保 异二聚体蛋白的生成
EA038920B1 (ru) * 2012-10-02 2021-11-10 Бристол-Майерс Сквибб Компани Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3166974A1 (fr) * 2014-07-11 2017-05-17 Genentech, Inc. Anticorps anti-pd-l1 et leurs utilisations
KR20170066546A (ko) * 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
WO2016081773A2 (fr) * 2014-11-19 2016-05-26 Mirna Therapeutics, Inc. Traitement anticancéreux combiné avec des inhibiteurs du c-met et des oligonucléotides synthétiques
US10544224B2 (en) * 2015-07-14 2020-01-28 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor
JP6878405B2 (ja) * 2015-07-29 2021-05-26 ノバルティス アーゲー Ｐｄ−１に対する抗体分子を含む組み合わせ治療
CA3007671A1 (fr) * 2015-12-17 2017-06-22 Novartis Ag Molecules d'anticorps anti-pd-1 et leurs utilisations

Also Published As

Publication number Publication date
KR20180094977A (ko) 2018-08-24
WO2017106810A3 (fr) 2017-10-26
HK1254635A1 (zh) 2019-07-26
IL259729A (en) 2018-07-31
RU2018125603A (ru) 2020-01-21
AU2020201057A1 (en) 2020-03-05
CA3007421A1 (fr) 2017-06-22
US20200261573A1 (en) 2020-08-20
US20210121563A1 (en) 2021-04-29
CN108697794A (zh) 2018-10-23
RU2018125603A3 (fr) 2020-04-09
EP3389713A2 (fr) 2018-10-24
WO2017106810A2 (fr) 2017-06-22
JP2019502695A (ja) 2019-01-31

Similar Documents

Publication Publication Date Title
US11858991B2 (en) LAG-3-binding molecules and methods of use thereof
AU2018260975B2 (en) Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
US20210121563A1 (en) Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
JP6955507B2 (ja) Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
AU2016306090B2 (en) 5-bromo-2,6-di-(1H-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
US20180177872A1 (en) Combination of PD-1 antagonist with an EGFR inhibitor
KR20180034588A (ko) Pd-1-결합 분자 및 그것의 사용 방법
TW202237655A (zh) 針對pd-1之抗體分子及其用途
WO2016122701A1 (fr) Anticorps anti-dr5 et molécules comprenant des domaines de liaison de dr5 de ceux-ci
CN112638942A (zh) 抗pd-l1抗体的给药方案及其用途
JP2022504802A (ja) ５ｔ４シングルドメイン抗体およびその治療組成物
JP2022504822A (ja) Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
AU2017279046A1 (en) Therapeutic uses of a c-Raf inhibitor
TW202302636A (zh) 靶向ｂｃｍａ、ｇｐｒｃ５ｄ及ｃｄ３之三特異性抗體
CN114181310A (zh) 抗tigit抗体、其药物组合物及用途
JP7378567B2 (ja) Ｌａｇ‐３結合分子及びその使用方法
RU2791192C2 (ru) Молекулы антител к cd73 и пути их применения
RU2745560C2 (ru) 5-бром-2,6-ди-(1н-пиразол-1-ил)пиримидин-4-амин для применения в лечении рака
EA041306B1 (ru) Агонистические антитела против icos и их применение
EA041483B1 (ru) Связывающие lag-3 молекулы и способы их применения

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted